期刊
CURRENT OPINION IN HEMATOLOGY
卷 9, 期 4, 页码 308-315出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00062752-200207000-00008
关键词
-
类别
资金
- NCI NIH HHS [R01 CA72614] Funding Source: Medline
Knowledge of signal transduction pathways has uncovered therapeutic targets for cancer. Based on genetic and biochemical studies of leukemia cells, inhibiting hyperactive Ras represents a rational therapeutic strategy for many hematologic malignancies. Because posttranslational processing by farnesyltransferase is essential for transformation by oncogenic Ras, specific inhibitors of this enzyme are being evaluated as cancer therapeutics. The authors review recent laboratory insights on farnesyltransferase biology and on the development of inhibitors, summarize preclinical and clinical data in myeloid malignancies, and briefly discuss other strategies of interfering with hyperactive Ras. (C) 2002 Lippincott Williams Wilkins, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据